Evidence map›Paper›PMID 38191550›Full record

ArticleNature communications2024

Compartments in medulloblastoma with extensive nodularity are connected through differentiation along the granular precursor lineage.

David R Ghasemi, Konstantin Okonechnikov, Anne Rademacher, Stephan Tirier, Kendra K Maass, Hanna Schumacher, Piyush Joshi, Maxwell P Gold, Julia Sundheimer, Britta Statz and 16 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
5.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors at 7 institutions in 6 countries.

David R Ghasemi *Hopp-Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.ORCID 0000-0002-3844-9933
Konstantin Okonechnikov *Hopp-Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Anne RademacherDivision of Chromatin Networks, German Cancer Research Center (DKFZ) and Bioquant, Heidelberg, Germany.ORCID 0000-0003-3054-3121
Stephan TirierDivision of Chromatin Networks, German Cancer Research Center (DKFZ) and Bioquant, Heidelberg, Germany.
Kendra K MaassHopp-Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Hanna SchumacherHeidelberg University, Faculty of Medicine, and Heidelberg University Hospital, Institute for Computational Biomedicine, Bioquant, Heidelberg, Germany.ORCID 0000-0003-2665-9236
Piyush JoshiHopp-Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Maxwell P GoldDepartment of Biological Engineering, Massachusetts Institute of Technology (MIT), Cambridge, MA, USA.ORCID 0000-0002-6814-8576
Julia SundheimerHopp-Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.ORCID 0009-0005-9296-8098
Britta StatzHopp-Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Ahmet S RifaiogluHeidelberg University, Faculty of Medicine, and Heidelberg University Hospital, Institute for Computational Biomedicine, Bioquant, Heidelberg, Germany.
Katharina BauerSingle-cell Open Lab, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Sabrina SchumacherDivision of Chromatin Networks, German Cancer Research Center (DKFZ) and Bioquant, Heidelberg, Germany.
Michele BortolomeazziSingle-cell Open Lab, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Felice GiangasperoDepartment of Radiological, Oncological and Anatomo-Pathological Sciences, Sapienza University of Rome, Rome, Italy.ORCID 0000-0001-5382-2380
Kati J ErnstHopp-Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.ORCID 0000-0002-8555-5907
Steven C CliffordWolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Newcastle upon Tyne, UK.ORCID 0000-0003-4893-2184
Julio Saez-RodriguezHeidelberg University, Faculty of Medicine, and Heidelberg University Hospital, Institute for Computational Biomedicine, Bioquant, Heidelberg, Germany.ORCID 0000-0002-8552-8976
David T W JonesHopp-Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.ORCID 0000-0002-2036-5141
Daisuke KawauchiDepartment of Biochemistry and Cellular Biology, National Center of Neurology and Psychiatry (NCNP), Tokyo, Japan.ORCID 0000-0002-1254-9725
Ernest FraenkelDepartment of Biological Engineering, Massachusetts Institute of Technology (MIT), Cambridge, MA, USA.
Jan-Philipp MallmSingle-cell Open Lab, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-7059-4030
Karsten RippeDivision of Chromatin Networks, German Cancer Research Center (DKFZ) and Bioquant, Heidelberg, Germany.ORCID 0000-0001-9951-9395
Andrey KorshunovHopp-Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany. andrey.korshunov@med.uni-heidelberg.de.
Stefan M PfisterHopp-Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany. s.pfister@kitz-heidelberg.de.ORCID 0000-0002-5447-5322
Kristian W PajtlerHopp-Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany. k.pajtler@kitz-heidelberg.de.ORCID 0000-0002-3562-6121
German Cancer Research Center · DEHeidelberg University · DEBroad Institute · USIstituto Neurologico Mediterraneo · ITMassachusetts Institute of Technology · USNational Center of Neurology and Psychiatry · JPNewcastle University · GB

Funding

Graduate Training in Computational and Systems BiologyT32GM087237 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BURGE, CHRISTOPHER B · 2009 to 2023
$4.6M
Identifying therapeutic pathways targeting medulloblastoma-immune cell interactionsU01CA253547 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI FRAENKEL, ERNEST, MESIROV, JILL P. · 2021 to 2025
$2.7M
Cancer Research UK DRCRPG-NOV22/100002NCI NIH HHS U01 CA253547NIGMS NIH HHS T32 GM087237
6 · The paper itself

Abstract

Medulloblastomas with extensive nodularity are cerebellar tumors characterized by two distinct compartments and variable disease progression. The mechanisms governing the balance between proliferation and differentiation in MBEN remain poorly understood. Here, we employ a multi-modal single cell transcriptome analysis to dissect this process. In the internodular compartment, we identify proliferating cerebellar granular neuronal precursor-like malignant cells, along with stromal, vascular, and immune cells. In contrast, the nodular compartment comprises postmitotic, neuronally differentiated malignant cells. Both compartments are connected through an intermediate cell stage resembling actively migrating CGNPs. Notably, we also discover astrocytic-like malignant cells, found in proximity to migrating and differentiated cells at the transition zone between the two compartments. Our study sheds light on the spatial tissue organization and its link to the developmental trajectory, resulting in a more benign tumor phenotype. This integrative approach holds promise to explore intercompartmental interactions in other cancers with varying histology.

Indexed as

Cerebellar NeoplasmsMedulloblastomaCell DifferentiationDisease ProgressionHistological TechniquesHumans

Identifiers

PMID38191550
PMCPMC10774372
OpenAlexW4390669721

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.